12 Dec 2022
ISB 1442
Poster: A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose- Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma
Jiang T. et al.
American Society of Hematology Annual Meeting
12 Dec 2022
ISB 1442
Poster: A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose- Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma
Jiang T. et al.
American Society of Hematology Annual Meeting
11 Dec 2022
ISB 1342
Poster: Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)
Mohan S. et al.
American Society of Hematology Annual Meeting
11 Dec 2022
ISB 1342
Poster: Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)
Mohan S. et al.
American Society of Hematology Annual Meeting
11 Dec 2022
ISB 1442
Poster: Preclinical Evaluation of ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of AML and T-ALL
Sammicheli S. et al.
American Society of Hematology Annual Meeting
11 Dec 2022
ISB 1442
Presentation: Preclinical Evaluation of ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of AML and T-ALL
Sammicheli S. et al.
Presentation at the American Society of Hematology Annual Meeting
10 Dec 2022
ISB 2001
ISB 2001, a First-in-Class Trispecific BCMA and CD38 T Cell Engager Designed to Overcome Mechanisms of Escape from Treatments for Multiple Myeloma by Targeting Two Antigens
Perro M. et al.
Presentation at the American Society of Hematology Annual Meeting
28 Jun 2022
Process Development
Optimization of a Cell Culture Clarification Platform Process With the Aim of Boosting the Recovery of Bispecific Antibodies
Mette R. et al.
ESACT2022 Conference
28 Jun 2022
Process Development
Increased Throughput in Upstream Development via Automated Feed Strategy Using Qubicon®
Schmid S. et al.
ESACT2022 Conference
27 Jun 2022
Process Development
Assessment Of The Impact Of The Milling Type And Production Site For Cell Culture Feed Production
Le Moal M. et al.
ESACT2022 Conference
10 Jun 2022
ISB 1442
ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of CD38+ Malignancies
Sammicheli S. et al.
EHA2022